Volume 67, Issue 1, Pages (January 2005)

Slides:



Advertisements
Similar presentations
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Features of Hypertrophic Cardiomyopathy.
Advertisements

Volume 62, Issue 6, Pages (December 2002)
Michael Allon, Michelle L. Robbin  Kidney International 
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Steven Fishbane, Jeffrey S. Berns, M.D.  Kidney International 
Treatment of acute renal failure
Long-term evolution of cardiomyopathy in dialysis patients
Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy
Beta blockers in the management of chronic kidney disease
Intensive hemodialysis—keeping the faith
The Case | Renal failure in a bodybuilder athlete
Volume 9, Issue 1, Pages (January 2012)
Erratum Heart Rhythm Volume 8, Issue 4, (April 2011)
Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.
Intensive hemodialysis—keeping the faith
Misconceptions and Facts About Hypertrophic Cardiomyopathy
C-reactive protein and dialysis access
Douglas L. Mann, MD, Michael A. Acker, MD, Mariell Jessup, MD, Hani N
Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2  Robert N. Foley, Charles A. Herzog, Allan.
Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real?  S. Andrulli, S. Di Filippo, F. Locatelli 
Cardiac Dysfunction Caused by Osimertinib
Homocysteine and risk in end-stage renal disease: a matter of context
Prediction of hypertension in chronic hemodialysis patients
Volume 80, Issue 9, Pages (November 2011)
The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis  Sai Subhodhini Reddy, Jean L. Holley 
Volume 81, Issue 2, Pages (January 2012)
Volume 74, Pages S19-S23 (December 2008)
Volume 77, Issue 2, Pages (January 2010)
The Effects of Candesartan on Left Ventricular Hypertrophy and Function in Nonobstructive Hypertrophic Cardiomyopathy  Martin Penicka, Pavel Gregor, Roman.
Ventricular Dilatation and Remodeling After Myocardial Infarction
Treatment of acute renal failure
Acute myocardial infarction in patients with end-stage renal disease
Anemia as a risk factor for cardiovascular disease
Volume 75, Issue 1, Pages (January 2009)
Blood pressure targets in hemodialysis patients
Bar chart of cardiac volumes and EF in the healthy individuals, HCM LVH− patients and HCM LVH+ patients. Blue bars show the indexed diastolic volumes (EDVI.
Volume 58, Issue 3, Pages (September 2000)
Yijian Huang, Rebecca Zhang, Steven D. Culler, Nancy G. Kutner 
Effects of hemodialysis on cardiac function
Volume 61, Issue 6, Pages (June 2002)
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Alternate-day dialysis may be needed for hemodialysis patients
Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia 
Long-term evolution of cardiomyopathy in dialysis patients
Miki Yokokawa, MD, Fred Morady, MD, FACC, Frank Bogun, MD, FACC 
Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis  N.-Y. Zalunardo, C.-L. Rose, I.W.Y.
Terry Behrend, Steven B. Miller, M.D  Kidney International 
A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related.
Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomes  Sr. Anne B. Bakewell, Rob M. Higgins, Mair.
Volume 70, Issue 3, Pages (August 2006)
Volume 72, Issue 5, Pages (November 1977)
Daily nocturnal home hemodialysis
Current status of maintenance hemodialysis in Beijing, China
Volume 70, Issue 8, Pages (October 2006)
Long-term outcome of dialysis patients in the United States with coronary revascularization procedures  Charles A. Herzog, M.D., Jennie Z. Ma, Allan J.
Volume 80, Issue 10, Pages (November 2011)
Charles A. Herzog  Kidney International 
Volume 74, Issue 7, Pages (October 2008)
Importance of blood pressure control in hemodialysis patient survival
Yutaka Koda, M.D., Shin-Ichi Nishi, Masashi Suzuki, Yoshihei Hirasawa 
The International Pediatric Peritonitis Registry: Starting to walk
Volume 67, Issue 6, Pages (June 2005)
Hemodialysis access failure: a call to action—revisited
E.F. Vonesh, J.J. Snyder, R.N. Foley, A.J. Collins 
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Volume 63, Issue 1, Pages (January 2003)
Characteristics of sudden death in hemodialysis patients
Presentation transcript:

Volume 67, Issue 1, Pages 333-340 (January 2005) Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients  Jiro Aoki, Yuji Ikari, Hiroyoshi Nakajima, Masaya Mori, Tokuichiro Sugimoto, Mitsuharu Hatori, Shuzou Tanimoto, Eisuke Amiya, Kazuhiro Hara, MD  Kidney International  Volume 67, Issue 1, Pages 333-340 (January 2005) DOI: 10.1111/j.1523-1755.2005.00086.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Representative case: a 71-year-old male patient with heart failure on dialysis for 2.8 years. Hypertrophic and bizarrely shaped myocytes (HE stain, 400×) (A). Fibrous tissue surrounds each myocyte (AZ stain, 400×) (B). C. Left ventriculography at end diastole: LVEDVI = 193mL/m2 (30° right anterior oblique) (C). Left ventriculography at end systole: EF = 22% (30° right anterior oblique) (D). Kidney International 2005 67, 333-340DOI: (10.1111/j.1523-1755.2005.00086.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Hypertrophic and bizarrely shaped myocytes with irregular enlarged nuclei. A 68-year-old male patient on dialysis for 7.3 years (HE stain, 400×) (A). A 39-year-old male patient not on dialysis (HE stain, 400×) (B). A 45-year-old female patient on dialysis for 1.9 years (C). Myocytes show disarray (HE stain, 400×) Kidney International 2005 67, 333-340DOI: (10.1111/j.1523-1755.2005.00086.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 A 56-year-old male patient on dialysis for 7.1 years (A). Widespread fibrosis is present, and interstitial fibrosis surrounds each myocyte (AZ stain, 400×). This patient died of ventricular arrhythmia 1.1 years after biopsy. A 56-year-old male patient on dialysis for 6.8 years (B). Only a little interstitial fibrosis is present (AZ stain, 400×). This patient had no cardiac events during 3.8 years of follow-up. Kidney International 2005 67, 333-340DOI: (10.1111/j.1523-1755.2005.00086.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Morphometric findings. Distribution of myocyte hypertrophy (A). Distribution of percent of LV fibrosis (B). Open boxes represent hemodialysis patients with DCM, and closed boxes represent non-hemodialysis patients with DCM. Kidney International 2005 67, 333-340DOI: (10.1111/j.1523-1755.2005.00086.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 5 Cumulative survival for cardiac death, group stratified by the extent of fibrosis. Continuous bold line indicates the dialysis group with an LV fibrosis area ≥30%. Dotted bold line indicates the dialysis group with an LV fibrosis area <30%. Continuous fine line indicates the control group with an LV fibrosis area ≥30%. Dotted fine line indicates the control group with an LV fibrosis area <30% (P < 0.0001, not including the control group with an LV fibrosis area ≥30%). Kidney International 2005 67, 333-340DOI: (10.1111/j.1523-1755.2005.00086.x) Copyright © 2005 International Society of Nephrology Terms and Conditions